Semaglutide

Semaglutide, also known by its research designation NN9535 and commercial names Ozempic, Wegovy, and Rybelsus (oral formulation), is a glucagon-like peptide-1 (GLP-1) receptor agonist developed for metabolic research applications. The compound functions as a GLP-1 receptor agonist that mimics the action of the endogenous hormone GLP-1. In research models, semaglutide enhances insulin secretion in a glucose-dependent manner, suppresses glucagon release, and slows gastric emptying. These coordinated actions collectively regulate blood glucose levels and reduce appetite through well-characterised physiological pathways. Extensive research demonstrates semaglutide's effects across multiple metabolic parameters. Studies indicate the compound improves glycaemic control in type 2 diabetes research models, reduces body weight in obesity studies, decreases appetite and caloric intake, lowers HbA1c levels, and reduces cardiovascular risk factors. The evidence grade is classified as A, reflecting robust data from multiple large-scale human trials that consistently demonstrate significant reductions in HbA1c and body weight. Whilst the research evidence for semaglutide's efficacy in improving glycaemic control and promoting metabolic research is substantial and well-documented, researchers should note that long-term safety data beyond five years remains limited. This consideration is particularly relevant for extended study designs examining chronic metabolic interventions.